Infliximab for the treatment of adults with psoriasis

Review decision - September 2010 information

Appendix A: Decision paper presented to the Institute's Guidance Executive (PDF 105 KB)

Review proposal - August 2010 information

Appendix A: provisional matrix of stakeholders (PDF 29 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 285 KB)

Review decision - July 2009  information

Review decision - December 2008 information

Review decision - December 2008: table of comments (PDF 43 KB)

Review Proposal - October 2008 information

Provisional matrix of consultees and commentators (MSWord 67 KB)

Psoriasis - infliximab: Final appraisal determination and comments on ACD information

Psoriasis - infliximab: Final appraisal determination (PDF 86 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 137 KB)

Consultee and commentator comments on the ACD

Commentators

Wyeth Pharmaceuticals (PDF 60 KB)

Merck Serono (PDF 32 KB)

Cochrane Skin Group (PDF 9.5 KB)

Professional and patient groups

Royal College of Physicians (PDF 63 KB)

Royal College of Paediatrics and Child Health (PDF 12 KB)

The Psoriasis Association (PDF 25 KB)

British Association of Dermatologists (PDF 16 KB)

Schering Plough Ltd (PDF 423 KB)

Expert comments on the ACD: Ms Karina Jackson, Clinical Expert nominated by the British Dermatological Nursing Group (PDF 40 KB)

Psoriasis - infliximab: Appraisal Consultation Document information

Psoriasis - infliximab: Evaluation report 

Psoriasis - infliximab: Schering-Plough Ltd (PDF 1.59 MB)

Psoriasis - infliximab: Evidence review group report (PDF 445 KB)

Pre-meeting briefing (PDF 175 KB)

Psoriasis - infliximab: Non-manufacturer submissions

The Psoriasis Association (PDF 54 KB)

Psoriatic Anthropathy Alliance (PDF 45 KB)

British Association of Dermatologists (PDF 51 KB)

British Dermatological Nursing Group (PDF 42 KB)

Royal College of General Practitioners (PDF 16 KB)

Royal College of Physicians (PDF 44 KB)

Psoriasis - infliximab: Manufacturer response to clarification letter

Manufacturer response A (PDF 239 KB)

Manufacturer response B (PDF 735 KB)

NICE clarification letter (PDF 27 KB)

Psoriasis - infliximab: Expert written personal statements

Griffiths (PDF 20 KB)

Barker (PDF 22 KB)

Jackson (PDF 23 KB)

Edwards (PDF 21 KB)

Jobling (PDF 20 KB)

Medicines concordance: Final scope (PDF 39 KB)

Medicines concordance: Final scope (PDF 39 KB)

Comments on draft scope and matrix and the Institute's response (PDF 51 KB)

Medicines concordance: Final scope (PDF 39 KB)

Psoriasis - infliximab:Appraisal consultation document (using ACD form features) information